This report came up on the Sjo forum. It's a large multi-center study. The top broad message is type 1 interferon alpha (IFN-α-2) levels are of particular interest in Sjo sub-types and prognostics. This is the exact one we take. HigherIFN-α-2 levels are negative prognostically. They suggest measuring this, along with other factors, for better trial design and prognostics. This is endogenous IFN-α-2 (synthesized by the body) vs recombinant medicine (PEG, Bes) although they are supposed to be identical.
This may explain the peculiar connection of the recombinant α-2 IFN we use to Sjo, as opposed to other autoimmunes, as seen in infrequent but regular posts here and as a "common" adverse event found in the Bes trial as I've posted.
May be for some pts the extra IFN α-2 goes to the wrong places. Another reminder to stay aware of any emergent indicators of risk.
acrjournals.onlinelibrary.w...
I had access to the full report but can't find it now.